CA
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVECOVER ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

CA Cancer J Clin 2009; 59:56-66
doi: 10.3322/caac.20004
© 2009 American Cancer Society
This Article
Right arrow Full Text Freely available
Right arrow Full Text (PDF) Freely available
Right arrow Freely available CME: Take the course for this article:
 Patient Adherence and Persistence with Oral Anticancer Treatment
Right arrow FREE NURSING CONTACT HOURS
Right arrow Submit a letter to the editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ruddy, K.
Right arrow Articles by Partridge, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ruddy, K.
Right arrow Articles by Partridge, A.

Patient adherence and persistence with oral anticancer treatment

Kathryn Ruddy, MD1, Erica Mayer, MD, MPH2 and Ann Partridge, MD, MPH3

1Clinical Fellow in Medicine, Brigham and Women's Hospital, Dana-Farber Cancer Institute, Boston, MA
2Instructor in Medicine, Brigham and Women's Hospital, Dana-Farber Cancer Institute, Boston, MA
3Assistant Professor of Medicine, Brigham and Women's Hospital, Dana-Farber Cancer Institute, Boston, MA

Corresponding author: Department of Breast Oncology, Dana-Farber Cancer Institute, Mayer 215, 44 Binney Street, Boston, MA, 02115; e-mail: kruddy{at}partners.org

To earn free CME credit or nursing contact hours for successfully completing the online quiz based on this article, go to http://CME.AmCancerSoc.org.

DISCLOSURES: Dr. Partridge has received honoraria for serving as a consultant to AstraZeneca and Novartis. No other conflicts of interest relevant to this article were reported.

Given the recent significant increase in the use of oral therapies in cancer management, an understanding of patients' adherence to and persistence with oral therapy is crucial. Nonadherence and early cessation may be substantial barriers to the delivery of valuable therapies, and may impair health. Potential obstacles to adherence and persistence include personal characteristics, treatment features, and system factors. Techniques for measuring adherence and persistence include self-report, pill counts, microelectronic monitoring systems (MEMS), prescription database analysis, and the assessment of serum or urine drug levels. This review article describes available data regarding adherence and persistence among patients with cancer, as well as studies of interventions to improve adherence. All reports of studies of adherence with oral cancer therapy that the authors could find on PubMed or in the reference sections of these PubMed-located articles were included. Adherence and persistence rates ranged from 16% to 100% with different therapies and different methods of measurement. Studies that included educational, behavioral, and multidimensional interventions to improve adherence were also described. CA Cancer J Clin 2009;59:56–66. © 2009 American Cancer Society.




This article has been cited by other articles:


Home page
 JAMAHome page
Y. Yang, D. Miao, and Y. Sun
Cognitive Behavioral Therapy Alone and With Medication for Persistent Insomnia
JAMA, September 9, 2009; 302(10): 1053 - 1053.
[Full Text] [PDF]

Home page
 Ann OncolHome page
K. J. Ruddy and A. H. Partridge
Adherence with adjuvant hormonal therapy for breast cancer
Ann. Onc., March 1, 2009; 20(3): 401 - 402.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVECOVER ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2009 by American Cancer Society.